Home » Biologics Discovery » Solution for Novel Biologics Modalities » In Vivo CAR-T Discovery Services

In Vivo CAR-T Discovery Services

CAR Lead and Targeting Binder Discovery

LVV/tLNP Packaging

Pharmacology Study

Access in vivo CAR-T discovery, using both viral and non-viral development approaches from CAR lead discovery, targeting binder discovery, LVV/LNP packaging, in vitro functional assays, and in vivo pharmacology studies. Downstream antibody, LNP, and LVV CMC development from early discovery to clinical stages.

In Vivo CAR-T Services
- Antibody discovery
- Pharmacology study
- CMC for antibody, mRNA–tLNP and tLVV
Antibody Discovery
- CAR lead and targeting binder
- Ready-to-use CD3 toolbox
Pharmacology Services
- Cell-based in vitro transfection
- In vivo study: PD/PK/Tox study

In Vivo CAR-T Discovery Services

Antibody Discovery

Packaging Service

Pharmacology Study

CAR lead discovery

Hybridoma
Single B cell screening
Human naïve library
sdAb naïve/immunized library

Targeting binder discovery

18 humanized sequences for rapid assembly and testing
Good thermal stability and sequence diversity with different germlines

mRNA-tLNP construction

Multiple RNA structures available: mRNA, saRNA, circRNA
LNP encapsulation and antibody conjugation

LVV packaging

5 business day to deliver lentivirus
1E+8 TU/ml guaranteed functional titer
Suitable for animal study

In vitro functional assay

Killing assays
- Cancer cell lines
- Overexpression cell lines
- Luciferase target cells
Jurkat or PBMC based in vitro transfection

In vivo pharmacology

Broad efficacy models: syngeneic, PBMC, HSC, B cell depletion
PK study: In vivo CAR expression and CAR-T persistence
Toxicology study: rodent & NHP

Case Study

Retargeted LVVs for CD19 CAR Delivery

Targeting antibodies used to retarget LVVs for the delivery of the CD19 CAR sequence. This case study covers the subsequent in vitro functional assays and in vivo pharmacology studies.

Download the Case Study to Discover the Results